Suven Life Sciences has posted impressive growth in net profit during the fourth quarter ended March 2018 and its standalone net profit increased by 56 per cent to Rs.62.51 crore from Rs.40.07 crore in the similar period of last year. The net sales also move up 19 per cent to Rs.208.29 crore from Rs.175 crore and its other income went up by 87 per cent to Rs.9.23 crore from Rs.4.94 crore. With strong jump in profits, EPS moved up to Rs.4.90 from Rs.3.17 in the last period. R&D expenditure, however, declined to Rs.16.92 crore from Rs.19.24 crore.

For the full yer ended March 2018, Suven's consolidated net sales increased by 13.6 per cent to Rs.612.58 crore from Rs.539.17 crore in the previous year. The sales from CRAMs activities improved by 15.5 per cent to Rs.596.88 crore and that from DDDSS declined slightly to Rs.14.27 crore from Rs.14.74 crore. Its net profit surge by 41.9 per cent to Rs.123.69 crore from Rs.87.19 crore. Its R&D expenditure declined to Rs.90.21 crore from Rs.99.15 crore. Its expenses on innovative R&D in drug discovery stood at Rs.58.5 crore as against Rs.64.9 crore in the previous year. Taxation provision increased to Rs.71.83 crore from Rs.35.88 crore which put pressure on bottom line. EPS for the full year improved to Rs.9.70 from Rs.6.84 in the last year.